Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET

Company Participants

Jackie Fouse – Chief Executive Officer

Sarah Gheuens – Chief Medical Officer

Richa Poddar – Chief Commercial Officer

Jonathan Biller – Chief Financial Officer and Head of Corporate Affairs

Holly Manning – Senior Director of Investor Relations

Conference Call Participants

Anupam Rama – J.P. Morgan

Marc Frahm – Cowen and Company

Greg Harrison – Bank of America

Mark Breidenbach – Oppenheimer

Matt Carter – Goldman Sachs

Andrew Berens – SVB Securities

Danielle Brill – Raymond James

Operator

Ladies and gentlemen, please stand by your conference call will begin momentarily. Once again, ladies and gentlemen, please stay on the line. Good morning, and welcome to the Agios First Quarter 2022 Conference Call. At this time, all participants are in listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios request. I would now like to turn the call over to Holly Manning, Senior Director of Investor Relations.

Holly Manning

Thank you, Operator. Good morning, everyone. And welcome to Agios's First Quarter 2022 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com. With me on the Call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer, Dr. Sarah Gheuens, our Chief Medical Officer, Richa Poddar, our Chief Commercial Officer, Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs, and Dr. Bruce Car, our Chief Scientific Officer who will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. With that, I will turn the call over to Jackie.

Jackie Fouse

Thanks, Holly. Good morning, everyone and thank you for joining our first quarter 2022 results call. The first quarter of 2022 was a milestone moment for Agios, as we received the U.S. FDA approval for PYRUKYND, a first-in-class PK activator and the first and only approved disease modifying treatment for adults living with pyruvate kinase deficiency. From the scientists to first hypothesize the potential utility of PK activation, to the chemist who designed our molecule, to the clinical trial coordinators who helped enroll our trials, people across our organization, both past and present, has played a role in this important milestone.